Literature DB >> 24269406

[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].

V M Asensio-Sánchez1, L Trujillo-Guzmán2, R Ramoa-Osorio2.   

Abstract

CASE REPORT: A woman, treated with immunomodulatory and immunosuppressive drugs for multiple sclerosis, developed macular oedema 4 months after oral fingolimod administration. The patient was previously seen by an ophthalmologist, with a normal anterior segment and funduscopic examination. Four months after the treatment she referred to decreased visual acuity in both eyes. The funduscopic and OCT examination now revealed cystoid macular oedema (CME). DISCUSSION: Attention to visual changes and periodic funduscopic examinations are an important part of monitoring while using fingolimod. In our patient early recognition and discontinuation of fingolimod did not result in resolution of the CME.
Copyright © 2011 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Agudeza visual; Edema macular; Esclerosis múltiple; Fingolimod; Irreversible; Macular oedema; Multiple sclerosis; Visual acuity

Mesh:

Substances:

Year:  2012        PMID: 24269406     DOI: 10.1016/j.oftal.2012.07.020

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  3 in total

Review 1.  Fingolimod: therapeutic mechanisms and ocular adverse effects.

Authors:  P Mandal; A Gupta; W Fusi-Rubiano; P A Keane; Y Yang
Journal:  Eye (Lond)       Date:  2016-11-25       Impact factor: 3.775

Review 2.  Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Juliana Reyes-Guanes; Estefanía Zapata-Bravo; Laura Mora-Muñoz; Juan Antonio Reyes-Hurtado; Luis Octavio Tierradentro-García; William Rojas-Carabali; Marcela Gómez-Suarez; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-10-28

3.  Diagnosis and Management of Fingolimod-Associated Macular Edema.

Authors:  Chunjiang Wang; Zhenzhen Deng; Liying Song; Wei Sun; Shaoli Zhao
Journal:  Front Neurol       Date:  2022-07-15       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.